Windlas Biotech Pvt. Ltd. (Windlas), a leading Indian pharmaceutical contract drug development and manufacturing organization, in partnership with Mateon Therapeutics, Inc. (Mateon), a US-based oncology company focusing on TGF-β inhibitors as therapies against cancers and infectious diseases, today launched an innovative drug-device therapy PulmoHeal + ARTIHealth as a complete respiratory wellness solution.
AI-app based platformARTIHealth™, developed by Mateon Therapeuticswill enable patients to monitor progress of their respiratory function over the time by enabling them to upload daily cough and speech recording and receiving feedback on the health of their lungs. The platform is a self-assessment and monitoring tool that provides >90% accurate feedback used for suitable self-care and remote healthcare.
This is part of a long-term joint development agreement with IBM Watson Health Research and Mateon, according to a communication from the company.
Mr Hitesh Windlass, MD, Windlas Biotech, commented,“Respiratory health took the biggest hit during the COVID-19 outbreak. Ayurveda has been a rich source of innovative treatments even in the modern world.
Windlas is bringing allopathic rigour of clinical trials to evaluate herbal products from traditional medicine. DrVuongTrieu, CEO and Chairman of Mateon said,“We have been working on the TGF-β inhibition pathway for last 18 years.
Its relevance in controlling COVID-19 symptoms has been widely accepted and confirmed by researchers across the world.
Artemisinin is a highly promising TGF-β inhibitor and opens the way to alleviating many respiratory illnesses.”Saran Saund, CBO, Mateon, commented,“We need to efficiently utilise the power of digital health as a critical enabler for transforming the health system”.